1 / 12

Korean ADNI … where are we now

Korean ADNI … where are we now. Seol-Heui Han, MD, PhD. On behalf of Preparatory Committee for K-ADNI. C linical Re search Center for D ementia o f South Korea (CREDOS). 2005. 2006. 2007. 2008. 2009. 2010. 2013. 2014. 2011. 2012. 9yr Project. 700,000 US dollars /yr.

jedidiah
Download Presentation

Korean ADNI … where are we now

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Korean ADNI… where are we now Seol-Heui Han, MD, PhD. On behalf of Preparatory Committee for K-ADNI

  2. ClinicalResearch Center for Dementia ofSouth Korea (CREDOS) 2005 2006 2007 2008 2009 2010 2013 2014 2011 2012 9yr Project 700,000 US dollars /yr Funded by the Ministry of Health, Welfare, and Family Affairs

  3. Primary focus of CREDOS Healthy, SMI aMCI Cognition AD svMCI SVaD Time

  4. CREDOS CREDOS protocols Neuropsychological tests Items for history Cognition ADL Behaviors Differential diagnoses Scales or questionnaires Korean Dementia Screening Questionnaire (K-DSQ) Barthel- index Instrumental ADL (Seoul IADL) NPI MMSE CDR GDS Hachinski ischemic scale Geriatric depression scale Lab Vitamin B12 Folate VDRL TSH/free T4 MRI Axial T2, T1, FLAIR, (GRE) Coronal T1

  5. CREDOS D-Matrix Healthy, SMI aMCI, AD svMCI, SIVD

  6. Designing k-adni

  7. K-ADNI: Organization Tree Advisory board ADNI: M. Weiner CREDOS PI:DL Na Stroke risk ADAS-Cog, CDR ADL,NPI, FBI Neurologic scale CSF tau, amyloid Apo E, GWAS Lipid, homocysteine, TFT MRI-VBM, DTI, fMRI FDG-PET, PIB-PET

  8. Main aim: Effects of SVD on Progression of AD Cognition Time

  9. Plan: 500 cases Cognition

  10. K-ADNI 5yr Longitudinal study 2010 2011 2012 2013 2014 2015 Recruitment N=500 Follow up NPT Biomarker Imaging NPT Biomarker Imaging NPT Biomarker Imaging NPT Biomarker Imaging NPT Biomarker Imaging NPT Biomarker Imaging Neuropsychological Tests SNSB, ADL,CGA-NPI, FBI Biomarker Blood: Apo E polymorphism, Genome-wide study CSF Imaging studies MRI PET: FDG-PET, PIB-PET

  11. Ready to go • Funding sources ($1.5 M/yr for 5 years) • Government • Private donations • Industry support

More Related